Centessa Pharmaceuticals plc American Depositary Shares (NASDAQ: CNTA)
The alleged false and misleading statements and omissions include, but are not limited to, that: (i) lixivaptan, the Company’s drug product, was less safe than the Company had represented; (ii) the Company overstated lixivaptan’s clinical effectiveness and commercial viability; (iii) ZF874, another of the Company’s drug products, was less safe than the Company had represented; (iv) the Company overstated ZF874’s clinical effectiveness and commercial viability while downplaying the drug’s safety issues; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.